Revenue from the global Vulvodynia Treatment Market is currently valued at USD 5.6 Billion, and is projected to top USD 8 Billion by 2028, increasing at an impressive CAGR of 6.3% over the period of 2022 to 2028.
| Attribute | Details |
|---|---|
| Global Vulvodynia Treatment Market Size (2022) | USD 5.6 billion |
| Revenue Forecast (2028) | USD 8 billion |
| Global Market Growth Rate (2022 to 2028) | 6.3% CAGR |
| North America Market Share | 30.2% |
Vulvodynia treatment currently accounts for 73.4% share of the global neuropathic pain market, with North America and Western Europe leading the way as far as demand is concerned.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 6.10% |
| H1, 2022 Projected | 6.28% |
| H1, 2022 Outlook | 6.18% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 10 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (+) 08 ↑ |
The comparative analysis and market growth rate of global vulvodynia treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, However, a positive BPS growth is expected in H1-2022 over H1- 2021 duration with 08 Basis Point Share (BPS).
The surge in the BPS values is associated with the advances in pain neuroscience and the central sensitization paradigm for the management of vulvodynia through a neurobiological stand-point.
Conversely, the decline in the BPS values observed was attributed to the reduced adoption of topical treatment options for vulvodynia, owed to its many side effects, thus reducing patient preference towards treatment regime. Moreover, less reported follow-ups after treatment have further resulted in the decline in the BPS values for the market.
The key developments in the market include the incorporation of physical therapy (massage therapy), combined with conversation therapy, and sexological treatment for vulvodynia and other chronic female disorders. Moreover, biofeedback therapy, local anaesthetics, nerve block injections, pelvic floor therapy and surgery have proven to be effective in the management of vulvodynia.
The market is highly influenced by regulatory dynamics, and licensing for drug distribution, under the impact of macro and industry factors. The market is subject to comprehensive medical research owed to government associated funding, and campaigns to promote disease indication for vulvodynia.
Vulvodynia is an unexplained, complex cause of chronic vulvar pain or discomfort that can affect women of all ages and in any reproductive phase. The disease's complicated genesis as well as the symptoms of concomitant pain syndrome make illness management challenging.
Vulvodynia pain has a bad impact on sexual health as well reproductive health. Although the symptoms of vulvodynia aren't life-threatening, they can nonetheless have a significant influence on one’s life. Physiology, emotions, experiences, beliefs, lifestyles, and relationships all have a role in sexual response. Any component that is disrupted can have an impact on sexual and reproductive health.
Vulvodynia treatment demand rose at a CAGR of 5.2% from 2013 to 2021. Several therapies have come about in recent years that aim to address the biological, psychological, and interpersonal variables that contribute to this illness. This is a critical aspect driving consistent growth of the global vulvodynia therapy market.
Better diagnostic techniques and disease models have increased our understanding of the disease phenotype, propelling the vulvodynia therapeutic industry forward. Vulvodynia treatment demand is predicted to increase at a high CAGR of 6.3% from 2022 to 2028, with the global market expected to cross a valuation of USD 8 Billion by 2028.
Vulvodynia treatment at home has been performed since ages, where antidepressants and anticonvulsants have raised to the top of the list of vulvodynia therapy options. Vulvodynia treatment at home can help reduce pain to some extent. Individuals may need to attempt a variety of vulvodynia treatment at home before determining which ones are the most effective. It is also notable that vulvodynia treatment over the counter can be risky and one should consult doctor beforehand.
Principal Consultant
“Anaesthetic Gels & Creams and Appropriate Diet Options Driving Market Growth”
Growing economic and social impact of vulvodynia is driving demand for vulvodynia therapies in different regions of the world. Rising awareness of the impact of vulvodynia on the healthcare systems in developed nations is also propelling the industry forward.
Growing knowledge of vulvodynia diagnostics among clinicians, particularly gynaecologists, is propelling the worldwide vulvodynia therapy market ahead. Advances in various therapeutic methods for vulvodynia management are projected to open up new opportunities for market players.
The industry's focus on multidisciplinary approaches to disease management has a positive impact on market prospects. A key trend driving vulvodynia demand growth is the increased acceptability of local anaesthetics in the form of gels or creams to reduce pain-related discomfort in the patient populations.
A good example is the increased demand for lidocaine gel or cream. Increased research on expanding first-line vulvodynia treatment is also fuelling the market's steady growth. It is also important not to repeatedly make use of over-the-counter vulvodynia treatment options without consulting a doctor.
The market will benefit from relentless research and development initiatives targeted at discovering a reliable therapeutic strategy for controlling vulvodynia. Unmet needs in vulvodynia therapy are likely to be addressed by the expanding number of psychophysical research programs.
A recent study shows that vulvodynia treatment diet plays an important role, and keeping patients on a particular diet can help recover from vulvodynia pain. Dieticians are now researching on particular vulvodynia treatment diets to lessen the discomfort.
Female sexual dysfunction has become a common problem worldwide, and can strike at any age. Female sexual dysfunction treatment performed under the guidance of a specialist can help overcome pain. Education and information on sexual health is also helping in raising awareness of female sexual dysfunction treatment across regions.
North America Handsomely Leading Global Vulvodynia Treatment Market
These vulvodynia treatment market insights shed light on regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The North America vulvodynia treatment market is expected to account for the highest market share of around 30.2% in the global landscape in 2022. A recent Harvard study showed that there are approximately 6 Million American women who are suffering from vulvodynia.
The vulvodynia treatment devices market in Western Europe and Eastern Europe are expected to be driven by rising popularity of vulvodynia treatment procedures, increasing medical research & development, etc. The Western Europe and Eastern Europe market together are set to account for 30.6 % of the global market share in 2022.
The Latin America vulvodynia treatment market is set account for 10.1% of the global market share in 2022. APEJ is expected to be the third-most lucrative market with 19.6% market share in 2022. This is because of rapidly increasing penetration of generics in China and India.
The vulvodynia treatment equipment market in the MEA region is expected to progress at a slightly slower rate than other regions, but this trend is anticipated to change by the end of the forecast period. In 2022, the market in MEA is set to account for 3.2% of the global market share.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Well-established Healthcare Infra in the USA Driving Vulvodynia Treatment
The United States is one of the top countries driving vulvodynia treatment demand. The country's prospects are being boosted by the presence of well-developed healthcare infrastructure and the availability of skilled medical staff.
Throughout the projected period, the United States market is expected to grow at a robust rate. The country is boosting its spending on biopharmaceutical research and development in order to develop cures for uncommon diseases, which bodes well for vulvodynia treatment system providers in the country.
Anticonvulsants Most Prescribed Vulvodynia Treatment Drugs
Anticonvulsants are medications that are used to prevent seizures or stop a series of seizures from occurring (convulsions). Anticonvulsants are the most commonly prescribed medications for vulvodynia treatment.
Gabapentin is the most effective anticonvulsant medicine for the treatment of vulvodynia. Gabapentin is a medicine that has long been known as an excellent pain reliever in chronic pain management. It consists of tablets that are taken orally and are effective for nerve pain relief. These tablets are used to treat a variety of disorders that affect the central nervous system, as well as discomfort in the spinal cord. Another anticonvulsant is pregabalin. It's quite similar to gabapentin, but it's said to have fewer side effects and believed to be more effective.
Tricyclic antidepressants (TCAs) are a type of drug that are primarily used to treat depression. A doctor can prescribe them in lesser amounts than those used to treat depression. These medications are given because they change the way nerve fibres convey pain signals.
Companies are looking for therapies and medications that might alleviate the discomfort associated with vulvodynia in order to meet the demand of an increasing number of patients. They are spending more on research and development as well as mergers and acquisitions to achieve this. As a result, this will help them increase their target bases by being able to cater to both, global and domestic audiences.
Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc are among the major vulvodynia treatment equipment manufacturers.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Drug Class, Mode of Administration, Distribution Channel, Region |
| Key Companies Profiled | Eli Lilly and Company; AstraZeneca Plc.; GlaxoSmithKline Plc.; Pfizer Inc.; Johnson & Johnson Services Inc.; Allergan plc |
| Pricing | Available upon Request |
The global vulvodynia treatment market is estimated to surge at a CAGR of 6.3% through 2028.
The global market for vulvodynia treatment is currently worth USD 5.6 Billion.
Key vulvodynia treatment product providers are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan.
The global vulvodynia treatment market is anticipated to cross a valuation of USD 8 Billion by 2028.
The Japan vulvodynia treatment market currently holds 6.3% share in the global market.
1. Executive Summary 2. Market Introduction 3. Vulvodynia Treatment Market View Point 4. Vulvodynia Treatment Market Dynamics 5. North America Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 6. Latin America Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 7. Western Europe Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 8. Eastern Europe Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 9. Asia Pacific Excluding Japan Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 10. Japan Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 11. Middle East and Africa Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 12. Forecast Factors: Relevance and Impact 13. Forecast Assumptions 14. Competition Landscape 14.1. GlaxoSmithKline plc. 14.2. AstraZeneca Plc. 14.3. Eli Lilly and Company 14.4. Merck & Co., Inc. 14.5. Pfizer Inc. 14.6. Johnson & Johnson Services, Inc. 14.7. Allergan plc. 14.8. Depomed Inc. 14.9. Par pharmaceutical 14.10. Vertical pharmaceutical 15. Global Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Region 15.1. North America 15.2. Western Europe 15.3. Eastern Europe 15.4. Latin America 15.5. Asia Pacific Excluding Japan 15.6. Japan 15.7. Middle East and Africa 16. Global Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Drug Class 16.1. Anticonvulsant 16.2. Tricyclic Antidepressant 16.3. Serotonin-norepinephrine reuptake inhibitors (SNRI) 16.4. Hormone 16.5. Nerve Block 16.6. Local Anesthetic 16.7. Others 17. Global Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Mode Of Administration 17.1. Oral 17.2. Topical 17.3. Injectable 18. Global Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Distribution Channel 18.1. Hospital Pharmacies 18.2. Retail Pharmacies 18.3. Drug Stores 18.4. Online Pharmacies 19. Global Vulvodynia Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 19.1. Market Size and Y-o-Y Growth 19.2. Absolute $ Opportunity 19.3. Value Chain 20. Assumptions and Acronyms Used 21. Research Methodology
Healthcare
October 2022
REP-GB-4400
222 pages
Explore Healthcare Insights
View Reports
Vulvodynia Treatment Market
